Part II: Interactive case—Clinical pearls of clozapine

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACYVolume 6, Issue 3 p. 312-318 PSAP IN JACCP Part II: Interactive case—Clinical pearls of clozapine Jonathan G. Leung Pharm.D., Jonathan G. Leung Pharm.D. orcid.org/0000-0003-3836-9375 Mayo Clinic, Rochester, MinnesotaSearch for more papers by this author Jonathan G. Leung Pharm.D., Jonathan G. Leung Pharm.D. orcid.org/0000-0003-3836-9375 Mayo Clinic, Rochester, MinnesotaSearch for more papers by this author First published: 10 March 2023 https://doi.org/10.1002/jac5.1765Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES Addington D, Abidi S, Garcia-Ortega I, Honer WG, Ismail Z. Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders. Can J Psychiatry. 2017; 62: 594–603. Bai YM, Chen JY, Chen TT, Lin CY, Chou P, Su TP, et al. Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients. Schizophr Res. 2009; 108: 122–6. Bird AM, Smith TL, Walton AE. Current treatment strategies for clozapine-induced sialorrhea. Ann Pharmacother. 2011; 45: 667–75. Blackman G, Oloyede E. Clozapine discontinuation withdrawal symptoms in schizophrenia. Ther Adv Psychopharmacol. 2021; 11: 20451253211032053. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012; 140: 159–68. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry. 1996; 153: 820–2. Citrome L, McEvoy JP, Saklad SR. Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychos. 2016; 10: 163–77. Clark SR, Warren NS, Kim G, Jankowiak D, Schubert KO, Kisely S, et al. Elevated clozapine levels associated with infection: a systematic review. Schizophr Res. 2018; 192: 50–6. Clarke WA, Salyer B, Hussey C, Gardiner JA, Johnson-Davis K, Milone MC. Multi-site evaluation of immunoassays for antipsychotic drug measurement in clinical samples. J Appl Lab Med. 2021; 6: 1541–50. Costa-Dookhan KA, Agarwal SM, Chintoh A, Tran VN, Stogios N, Ebdrup BH, Sockalingam S, Rajji TK, Remington GJ, Siskind D, Hahn MK The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opin Drug Saf 2020; 19: 43–57. Couchman L, Morgan PE, Spencer EP, Flanagan RJ. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. Ther Drug Monit. 2010; 32: 438–47. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007; 18: 39–60. de Leon J, Ruan CJ, Verdoux H, Wang C. Clozapine is strongly associated with the risk of pneumonia and inflammation. Gen Psychiatr. 2020a; 33:e100183. de Leon J, Sanz EJ, De Las Cuevas C. Data from the World Health Organization's pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophr Bull. 2020b; 46: 1–3. de Leon J, Sanz EJ, Norén GN, de las Cuevas C. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics. World Psychiatry. 2020c; 19: 120–1. de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, et al. An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry. 2021; 55: 73–86. https://doi.org/10.1055/a-1625-6388 Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology. 1991; 41: 369–71. Eagles SK, Gross AS, McLachlan AJ. The effects of cruciferous vegetable-enriched diets on drug metabolism: a systematic review and meta-analysis of dietary intervention trials in humans. Clin Pharmacol Ther. 2020; 108: 212–27. Every-Palmer S, Ellis PM, Nowitz M, Stanley J, Grant E, Huthwaite M, et al. The Porirua protocol in the treatment of clozapine-induced gastrointestinal hypomotility and constipation: a pre- and post-treatment study. CNS Drugs. 2017a; 31: 75–85. Every-Palmer S, Newton-Howes G, Clarke MJ. Pharmacological treatment for antipsychotic-related constipation. Cochrane Database Syst Rev. 2017b; 1: CD011128. Every-Palmer S, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H, et al. Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. EBioMedicine. 2016; 5: 125–34. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004; 76: 178–84. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014; 109(Suppl 1): S2–S27. Frankenburg FR, Kando JC, Centorrino F, Gilbert JM. Bladder dysfunction associated with clozapine therapy. J Clin Psychiatry. 1996; 57: 39–40. Grainger BT, Arcasoy MO, Kenedi CA. Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: a systematic review of the literature. Eur J Haematol. 2019; 103: 277–86. Harrison-Woolrych M, Skegg K, Ashton J, Herbison P, Skegg DCG. Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study. Br J Psychiatry. 2011; 99: 140–4. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000; 157: 975–81. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005; 66: 1116–21. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018; 51: 9–62. Hiluy JC, Nazar BP, Gonçalves WS, Coutinho W, Appolinario JC Effectiveness of pharmacologic interventions in the management of weight gain in patients with severe mental illness: a systematic review and meta-analysis. Prim Care Companion CNS Disord 2019; 21: 19r02483. Hynes C, Keating D, McWilliams S, Madigan K, Kinsella A, Maidment I, et al. Glasgow Antipsychotic Side-effects Scale for Clozapine—development and validation of a clozapine-specific side-effects scale. Schizophr Res. 2015; 168: 505–13. Ingimarsson O, MacCabe JH, Haraldsson M, Jónsdóttir H, Sigurdsson E Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. BMC Psychiatry 2016; 16: 441. Institute for Safe Medication Practices (ISMP). Medication safety alert! Potential for severe cardiovascular effects when restarting clozapine; January 13, 2022. Jeong SH, Kim JH, Ahn YM, Lee KY, Kim SW, Jung DC, et al. A 2-year prospective follow-up study of lower urinary tract symptoms in patients treated with clozapine. J Clin Psychopharmacol. 2008; 28: 618–24. Jessurun NT, Derijks HJ, van Marum RJ, Jongkind A, Giraud EL, van Puijenbroek E, et al. Body weight gain in clozapine-treated patients: is norclozapine the culprit? Br J Clin Pharmacol. 2021; 88: 853–7. https://doi.org/10.1111/bcp.14992 John AP, Ko EKF, Dominic A. Delayed initiation of clozapine continues to be a substantial clinical concern. Can J Psychiatry. 2018; 63: 526–31. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45: 789–96. Kang BJ, Cho MJ, Oh JT, Lee Y, Chae BJ, Ko J. Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS? Hum Psychopharmacol. 2006; 21: 387–91. Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020; 177: 868–72. Kelly DL, Ben-Yoav H, Payne GF, Winkler TE, Chocron SE, Kim E, et al. Blood draw barriers for treatment with clozapine and development of a point-of-care monitoring device. Clin Schizophr Relat Psychos. 2018a; 12: 23–30. Kelly DL, Freudenreich O, Sayer MA, Love RC Addressing barriers to clozapine underutilization: a national effort. Psychiatr Serv 2018b; 69: 224–7. Khan Z, Miller EA, Pervaiz AM. Clozapine intoxication in a patient on chronic use with a short-term noncompliance. Cureus. 2021; 13:e16578. Knoph KN, Morgan RJ III, Palmer BA, Schak KM, Owen AC, Leloux MR, et al. Clozapine-induced cardiomyopathy and myocarditis monitoring: a systematic review. Schizophr Res. 2018; 199: 17–30. Koponen HJ, Leinonen E, Lepola U. Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol. 1996; 6: 69–71. Kreinin A, Miodownik C, Mirkin V, Gaiduk Y, Yankovsky Y, Bersudsky Y, et al. Double-blind, randomized, placebo-controlled trial of metoclopramide for hypersalivation associated with clozapine. J Clin Psychopharmacol. 2016; 36: 200–5. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 1995; 152: 179–82. Kuo CJ, Yang SY, Liao YT, Chen WJ, Lee WC, Shau WY, et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull. 2013; 39: 648–57. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry. 1992; 149: 689–90. Larsen JR, Svensson CK, Vedtofte L, Jakobsen ML, Jespersen HS, Jakobsen MI, et al. High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. CNS Spectr. 2019; 24: 441–52. Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiat. 2017; 74: 719–28. LeBlaye I, Donatini B, Hall M, Krupp P. Acute overdosage with clozapine: a review of the available clinical experience. Pharmaceutical Med. 1992; 6: 169. Lee MJ, Kim CE. Use of aripiprazole in clozapine induced enuresis: report of two cases. J Korean Med Sci. 2010; 25: 333–5. Légaré N, Grégoire CA, de Benedictis L, Dumais A. Increasing the clozapine:norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. Med Hypotheses. 2013; 80: 689–91. Lenoir C, Daali Y, Rollason V, Curtin F, Gloor Y, Bosilkovska M, et al. Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail. Clin Pharmacol Ther. 2021a; 109: 1668–76. Lenoir C, Terrier J, Gloor Y, Curtin F, Rollason V, Desmeules JA, et al. Impact of SARS-CoV-2 infection (COVID-19) on cytochromes P450 activity assessed by the Geneva cocktail. Clin Pharmacol Ther. 2021b; 110: 1358–67. Leung JG, Cusimano J, Gannon JM, Milgrom O, Valcourt SC, Stoklosa JB, et al. Addressing clozapine under-prescribing and barriers to initiation: a psychiatrist, advanced practice provider, and trainee survey. Int Clin Psychopharmacol. 2019; 34: 247–56. Leung JG, Nelson S, Takala CR, Gören JL. Infection and inflammation leading to clozapine toxicity and intensive care: a case series. Ann Pharmacother. 2014; 48: 801–5. Leung JG, Rakocevic DB, Courtis SN, Leloux MR, Allen ND. Iatrogenic clozapine intoxication after hospital admission: a case-based rationale for an inpatient pharmacy clozapine monitoring service. J Am Pharm Assoc (2003). 2022; 62:S1544-3191(22)00151-0. Lin CC, Bai YM, Chen JY, Lin CY, Lan TH. A retrospective study of clozapine and urinary incontinence in Chinese in-patients. Acta Psychiatr Scand. 1999; 100: 158–61. Love RC, Kelly DL, Freudenreich O, Sayer MA. Clozapine underutilization: addressing the barriers. Alexandria, VA:National Association of State Mental Health Program Directors; 2016. Lowe EJ, Ackman ML. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother. 2010; 44: 727–32. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry. 2004; 65: 766–71. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) [published correction appears in Arch Gen Psychiatry 2003;60:735]. Arch Gen Psychiatry. 2003; 60: 82–91. Meyer JM, Cummings MA. Lubiprostone for treatment-resistant constipation associated with clozapine use. Acta Psychiatr Scand. 2014; 130: 71–2. Meyer JM, Proctor G, Cummings MA, Dardashti LJ, Stahl SM. Ciprofloxacin and clozapine: a potentially fatal but underappreciated interaction. Case Rep Psychiatry. 2016; 2016: 5606098–7. Montville DJ, Lindsey JM, Leung JG. Fluctuation between cigarette smoking and use of electronic nicotine delivery systems: impact on clozapine concentrations and clinical effect. Mental Health Clin. 2021; 11: 365–8. Mubaslat O, Lambert T. The effect of sublingual atropine sulfate on clozapine-induced hypersalivation: a multicentre, randomized placebo-controlled trial. Psychopharmacology (Berl). 2020; 237: 2905–15. Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018; 138: 101–9. Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang YT, Schulte PFJ, et al. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016; 30: 149–61. O'Dea CJ, Brookes JH, Wattchow DA. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Colorectal Dis. 2010; 12: 540–8. Osborne IJ, McIvor RJ. Clozapine-induced myoclonus: a case report and review of the literature. Ther Adv Psychopharmacol. 2015; 5: 351–6. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology. 1994; 44: 2247–9. Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008; 69: 759–68. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991; 148: 231–5. Poetter CE, Stewart JT. Treatment of clozapine-induced constipation with bethanechol. J Clin Psychopharmacol. 2013; 33: 713–4. Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl). 2013; 225: 505–18. Røge R, Møller BK, Andersen CR, Correll CU, Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res. 2012; 140: 204–13. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011; 45: 458–65. Sambhi RS, Puri R, Jones G. Interaction of clozapine and ciprofloxacin: a case report. Eur J Clin Pharmacol. 2007; 63: 895–6. Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. 2020; 81: 19cs13169. Schoretsanitis G, Kane JM, Ruan CJ, Spina E, Hiemke C, de Leon J. A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol. 2019; 12: 603–21. Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother. 2006; 40: 683–8. Schulte P, Bogers J, Bond-Veerman SRT, Cohen D. Moving forward with clozapine. Acta Psychiatr Scand. 2020; 142: 75–7. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002; 47: 27–38. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009; 70: 1041–50. Singh B, Hughes AJ, Roerig JL. Comfort level and barriers to the appropriate use of clozapine: a preliminary survey of US psychiatric residents. Acad Psychiatry. 2020; 44: 53–5. Siskind D, Honer WG, Clark S, Correll CU, Hasan A, Howes O, Kane JM, Kelly DL, Laitman R, Lee J, MacCabe JH, Myles N, Nielsen J, Schulte PF, Taylor D, Verdoux H, Wheeler A, Freudenreich O Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci 2020; 45:200061. Sockalingam S, Shammi C, Remington G. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2009; 70: 1114–9. Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia AG, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl). 2000; 148: 83–9. Spina E, Barbieri MA, Cicala G, de Leon J. Clinically relevant interactions between atypical antipsychotics and anti-infective agents. Pharmaceuticals. 2020; 13: 439. Stark A, Scott J. A review of the use of clozapine levels to guide treatment and determine cause of death. Aust N Z J Psychiatry. 2012; 46: 816–25. Stoecker ZR, George WT, O'Brien JB, Jancik J, Colon E, Rasimas JJ. Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. Int Clin Psychopharmacol. 2017; 32: 155–60. Suhas S, Manchegowda S, Venkatasubramanian G, Kumar V. Clozapine and oral contraceptives-implications beyond pharmacokinetics: a case report. J Clin Psychopharmacol. 2021; 41: 487–90. Tanzer TD, Brouard T, Pra SD, Warren N, Barras M, Kisely S, et al. Treatment strategies for clozapine-induced hypotension: a systematic review. Ther Adv Psychopharmacol. 2022; 12: 20451253221092931. Tio N, Schulte PFJ, Martens HJM. Clozapine intoxication in COVID-19. Am J Psychiatry. 2021; 178: 123–7. Tomulescu S, Uittenhove K, Boukakiou R. Managing recurrent clozapine-induced constipation in a patient with resistant schizophrenia. Case Rep Psychiatry. 2021; 2021: 9649334–4. Varma S, Bishara D, Besag FM, Taylor D. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol. 2011; 1: 47–66. Wagner E, McMahon L, Falkai P, Hasan A, Siskind D. Impact of smoking behavior on clozapine blood levels—a systematic review and meta-analysis. Acta Psychiatr Scand. 2020; 142: 456–66. Wagner E, Siafis S, Fernando P, Falkai P, Honer WG, Röh A, et al. Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review. Transl Psychiatry. 2021; 11: 487. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999; 156: 990–9. Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Hartter S, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol. 1998; 18: 2–9. Wieruszewski PM, Nelson S, Wittwer ED, Leung JG. Vasopressor-refractory shock from clozapine overdose treated with synthetic angiotensin II infusion. Crit Care Explor. 2020; 2:e0185. Williams AM, Park SH. Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs. 2015; 29: 101–11. Yartsev A, Peisah C. Caffeine-clozapine interaction associated with severe toxicity and multiorgan system failure: a case report. BMC Psychiatry. 2021; 21: 192. Zhuo C, Xu Y, Wang H, Zhou C, Liu J, Yu X, et al. Clozapine induces metformin-resistant prediabetes/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia. J Affect Disord. 2021; 295: 163–72. Volume6, Issue3March 2023Pages 312-318 ReferencesRelatedInformation